Clinical Trial OAKS and DERBY: Efficacy and safety of APL-2 in the treatment of geographic atrophy secondary to AMD 10/10/2018
A randomized, double-masked, multicenter, phase III clinical trial to evaluate the safety and efficacy of a new treatment, APL-2, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Patients with 60 years or older with GA and without concomitant or previous neovascular (wet) AMD. Further eligibility criteria applies.
To establish the safety and efficacy of APL-2 as determined mainly by change in GA lesion size at month 12 as compared to baseline in treated vs untreated patients.
About the drug
APL-2 (15 mg/0.1 ml) is an inhibitor of Complement protein C3 delivered by intravitreal injection.
Who can participate
Patients with GA secondary to AMD with a visual acuity in the study eye equal or better than 20/320 and a lesion size between 2.5 and 17.5 mm2, who have no current or prior history of wet AMD and who have not received treatment for wet AMD.